Defining and targeting adaptations to oncogenic KRAS G12C inhibition using quantitative temporal proteomics
Preprint
Abstract
Covalent inhibitors of the KRAS G12C oncoprotein have recently been developed and are being evaluated in clinical trials. Resistance to targeted therapies is common and likely to limit long-term efficacy of KRAS inhibitors (KRASi). To identify pathways of adaptation to KRASi and to predict drug combinations that circumvent resistance, we used a mass spectrometry-based quantitative temporal proteomics and bioinformatics workflow to profile the temporal proteomic response to KRAS G12C inhibition in pancreatic and lung cancer 2D and 3D cellular models. We quantified 10,805 proteins across our datasets, representing the most comprehensive KRASi proteomics effort to date. Our data reveal common mechanisms of acute and long-term response between KRAS G12C -driven tumors. To facilitate discovery in the cancer biology community, we generated an interactive ‘KRASi proteome’ website ( https://manciaslab.shinyapps.io/KRASi/ ). Based on these proteomic data, we identified potent combinations of KRASi with PI3K, HSP90, CDK4/6, and SHP2 inhibitors, in some instances converting a cytostatic response to KRASi monotherapy to a cytotoxic response to combination treatment. Overall, using our quantitative temporal proteomics-bioinformatics platform, we have comprehensively characterized the proteomic adaptations to KRASi and identified combinatorial regimens to induce cytotoxicity with potential therapeutic utility.Keywords
All Related Versions
- Published version: Cell Reports, 30 (13), 4584.
This publication has 72 references indexed in Scilit:
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerNature Medicine, 2019
- Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer CellsCancer Research, 2018
- Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolismNature Communications, 2017
- The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistanceOncotarget, 2016
- Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic CancerClinical Cancer Research, 2015
- Drugging the undruggable RAS: Mission Possible?Nature Reviews Drug Discovery, 2014
- Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug TargetsPLOS ONE, 2014
- KRAS: feeding pancreatic cancer proliferationTrends in Biochemical Sciences, 2014
- Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor GanetespibMolecular Cancer Therapeutics, 2012
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal AdenocarcinomaCancer Discovery, 2012